A Human Autoimmune Organoid Model Reveals IL-7 Function in Coeliac Disease
Authors
Affiliations
In vitro models of autoimmunity are constrained by an inability to culture affected epithelium alongside the complex tissue-resident immune microenvironment. Coeliac disease (CeD) is an autoimmune disease in which dietary gluten-derived peptides bind to the major histocompatibility complex (MHC) class II human leukocyte antigen molecules (HLA)-DQ2 or HLA-DQ8 to initiate immune-mediated duodenal mucosal injury. Here, we generated air-liquid interface (ALI) duodenal organoids from intact fragments of endoscopic biopsies that preserve epithelium alongside native mesenchyme and tissue-resident immune cells as a unit without requiring reconstitution. The immune diversity of ALI organoids spanned T cells, B and plasma cells, natural killer (NK) cells and myeloid cells, with extensive T-cell and B-cell receptor repertoires. HLA-DQ2.5-restricted gluten peptides selectively instigated epithelial destruction in HLA-DQ2.5-expressing organoids derived from CeD patients, and this was antagonized by blocking MHC-II or NKG2C/D. Gluten epitopes stimulated a CeD organoid immune network response in lymphoid and myeloid subsets alongside anti-transglutaminase 2 (TG2) autoantibody production. Functional studies in CeD organoids revealed that interleukin-7 (IL-7) is a gluten-inducible pathogenic modulator that regulates CD8 T-cell NKG2C/D expression and is necessary and sufficient for epithelial destruction. Furthermore, endogenous IL-7 was markedly upregulated in patient biopsies from active CeD compared with remission disease from gluten-free diets, predominantly in lamina propria mesenchyme. By preserving the epithelium alongside diverse immune populations, this human in vitro CeD model recapitulates gluten-dependent pathology, enables mechanistic investigation and establishes a proof of principle for the organoid modelling of autoimmunity.
Adapting systems biology to address the complexity of human disease in the single-cell era.
Fischer D, Villanueva M, Winter P, Shalek A Nat Rev Genet. 2025; .
PMID: 40065155 DOI: 10.1038/s41576-025-00821-6.
Panahipour L, Kargarpour Z, Mildner M, Kuhtreiber H, Gruber R Sci Rep. 2025; 15(1):3661.
PMID: 39881164 PMC: 11779933. DOI: 10.1038/s41598-025-86791-5.
Boosting human immunology: harnessing the potential of immune organoids.
Moll M, Baumjohann D EMBO Mol Med. 2025; 17(3):385-394.
PMID: 39870882 PMC: 11903751. DOI: 10.1038/s44321-025-00193-8.
Gardell J, Maurer M, Childs M, Pham M, Meengs B, Julien S Front Immunol. 2024; 15:1452537.
PMID: 39559361 PMC: 11570885. DOI: 10.3389/fimmu.2024.1452537.
Engineering human immune organoids for translational immunology.
Suhito I, Sunil C, Tay A Bioact Mater. 2024; 44:164-183.
PMID: 39474315 PMC: 11513670. DOI: 10.1016/j.bioactmat.2024.10.010.